This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. S Articles by Peters, B. S Search for Related Content Social Bookmarking                         What's this?

Review: Clinical aspects of the management of HIV lipodystrophy

Department of Chemical Pathology, St. Thomas' Hospital, London, UK, Anthony.Wierzbicki{at}kcl.ac.uk

Scott D Purdon

Department of Patient Relations, Pharmaceuticals International, GlaxoSmithKline, Brentford, Middlesex, UK

Timothy C Hardman

Niche Science & Technology Ltd, 96 Wolsey Drive, Kingston-Upon-Thames, Surrey, UK

Ranjababu Kulasegaram

HIV Unit, Harrison Wing, St. Thomas' Hospital, London, UK

Barry S Peters

HIV Unit, Harrison Wing, St. Thomas' Hospital, London, UK

Chronic complications of human immunodeficiency virus (HIV) and highly active retroviral therapy have become increasingly relevant as life expectancy for HIV patients has improved and the affected population ages. HIV-associated lipodystrophy syndrome is characterised by an abnormal fat distribution syndrome associated with metabolic disturbances including insulin resistance, and deranged glucose and lipid metabolism. It is associated with increased risks of progression to type 2 diabetes and cardiovascular disease.

Lipodystrophy is a clinical diagnosis and mostly subjective as standardised diagnostic criteria have not yet been defined. Several therapeutic interventions have been investigated including lifestyle therapy, vitamin supplements, switching antiretroviral therapy and specific therapies for insulin resistance and hyperlipidaemia. Current management options for HIV associated lipodystrophy are limited and are mostly based on avoidance of risk factors and switching of antiretroviral drugs. Therapies to improve insulin resistance have been tried but they are frequently ineffective as are lipid-lowering drugs. Interest in anabolic agents has been resurrected and new clinical data suggest that HIV-associated lipodystrophy growth hormone releasing factor therapy may have a beneficial role in the treatment of HIV-associated lipodystrophy. However, there still remains a need for robust prospective cohort studies and well designed intervention trials to resolve the aetiology and define the best treatment for this complication of HIV disease and its treatment.

Key Words: cardiovascular risk • cholesterol • diabetes • human immunodeficiency virus • lipodystrophy • treatment • triglycerides.

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 3, 113-119 (2008)
DOI: 10.1177/14746514080080030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Hakeem, I. W Campbell, and D. N. Bhattacharyya HIV-associated lipodystrophy - a new metabolic syndrome The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 129 - 134. [Abstract] [PDF]